Diabetic Nephropathy Market to Grow at a Substantial Growth Rate by 2032, Assesses DelveInsight |Key Players in the Market - Prokidney, Inversago, Palatin Technologies, Lexicon, Daiichi Sankyo, CSL Behring
Advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development. The diabetic nephropathy market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming therapies during the forecast period.
New York, USA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- *Diabetic Nephropathy Market to Grow at a Substantial Growth Rate by 2032, Assesses DelveInsight |Key Players in the Market - Prokidney, Inversago, Palatin Technologies, Lexicon, Daiichi Sankyo, CSL Behring*
*Advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development. The diabetic nephropathy market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming therapies during the forecast period.*
DelveInsight’s *Diabetic Nephropathy Market Insights* report includes a comprehensive understanding of current treatment practices, diabetic nephropathy emerging drugs, market share of individual therapies, and current and forecasted diabetic nephropathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
*Key Takeaways from the Diabetic Nephropathy Market Report*
· As per DelveInsight’s analysis, the diabetic nephropathy market size was found to be *USD 9.2 billion* in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· As per DelveInsight estimates, the total prevalent population of diabetic nephropathy in 7MM was estimated to be around *28 million* cases in 2021 and is expected to increase during the study period (2019–2032).
· Leading diabetic nephropathy companies such as *Prokidney, Inversago Pharma Inc., Palatin Technologies, Inc, Lexicon Pharmaceuticals, Daiichi Sankyo, CSL Behring, *and others are developing novel diabetic nephropathy drugs that can be available in the diabetic nephropathy market in the coming years.
· Some of the key therapies for diabetic nephropathy treatment include *Renal Autologous Cell Therapy (REACT), INV-202, Bremelanotide, Ambrisentan and Sotagliflozin, Esaxerenone, CSL346**, *and others.
Discover which therapies are expected to grab the major diabetic nephropathy market share @ *Diabetic Nephropathy Market Report*
*Diabetic Nephropathy Overview*
Diabetic nephropathy, also known as diabetic kidney disease (DKD), is a chronic kidney condition that develops in individuals with diabetes. This condition arises when elevated blood glucose levels damage the kidneys. Diabetic nephropathy is a prominent contributor to chronic kidney disease and end-stage renal disease (ESRD). ESRD refers to a state where the kidneys can no longer meet the body’s everyday needs, potentially leading to kidney failure, which can be life-threatening. The risk factors for diabetic nephropathy include smoking, comorbidities, and an age bracket of 62-65 years and above. It’s crucial to be aware that individuals in the early stages of this condition may not exhibit any symptoms. A diagnosis of diabetic nephropathy typically involves specific blood and urine tests. It is crucial to perform urine analysis and accurately document supine and erect blood pressure history. Additionally, measuring albumin levels is essential, as it is the earliest clinically detectable sign of this condition.
*Diabetic Nephropathy Epidemiology Segmentation*
The diabetic nephropathy epidemiology section provides insights into the historical and current diabetic nephropathy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The *diabetic nephropathy market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
· Diabetic Nephropathy Prevalent Cases
· Diabetic Nephropathy Gender-Specific Cases
· Diabetic Nephropathy Age-Specific Cases
· Diabetic Nephropathy Stage-Specific Cases
Download the report to understand which factors are driving diabetic nephropathy epidemiology trends @ *Diabetic Nephropathy Epidemiological Insights*
*Diabetic Nephropathy Treatment Market *
Diabetic nephropathy presents as a clinical condition characterized by persistent albuminuria and a gradual decline in kidney function, typically associated with a distinctive glomerular disease pattern. Diabetic nephropathy is closely linked to cardiovascular events and significantly impacts overall survival. The primary approach to managing albuminuria in patients involves maintaining blood pressure within a healthy range and utilizing angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to slow the progression of kidney dysfunction. However, it’s important to note that these treatments do not directly reduce the occurrence of cardiovascular events. Additionally, effective glycemic control is crucial for delaying or potentially preventing nephropathy and diabetes-related complications, which can pose challenges even for seasoned healthcare professionals.
In recent years, there has been a significant shift in the field of diabetes management, with the emergence of sodium/glucose co-transporter-2 (SGLT2) inhibitors at the forefront. These inhibitors have proven effective in lowering blood sugar levels, reducing blood pressure, slowing the decline of kidney function, and improving cardiovascular health. In 2019, the American Diabetes Association recommended the inclusion of SGLT2 inhibitors in the treatment of diabetic kidney disease.
One of the pioneering SGLT2 inhibitors is Invokana (canagliflozin), which was the first to gain approval for treating type 2 diabetes patients with diabetic nephropathy. However, its utilization was limited due to concerns about a potential increased risk of amputations. Notably, in August 2020, the US FDA revisited this issue and, based on new data from three clinical trials, removed the Boxed Warning regarding amputation risk from canagliflozin.
Invokana is presently available in both the United States and Europe. Furthermore, a newer formulation, *Vokanamet (EU)*, a fixed-dose combination of *canagliflozin and metformin, and Invokamet (US)*, are accessible for the treatment of type 2 diabetes patients with CKD. These combination drugs offer a convenient and effective alternative to the separate administration of canagliflozin and metformin.
Learn more about the FDA-approved drugs for diabetic nephropathy @ *Drugs for* *Diabetic Nephropathy Treatment** *
*Key Diabetic Nephropathy Therapies and Companies*
· Renal Autologous Cell Therapy (REACT): Prokidney
· INV-202: Inversago Pharma Inc.
· Bremelanotide: Palatin Technologies, Inc
· Ambrisentan and Sotagliflozin: Lexicon Pharmaceuticals
· Esaxerenone: Daiichi Sankyo
· CSL346: CSL Behring
To know more about diabetic nephropathy clinical trials, visit @ *Diabetic Nephropathy Treatment Drugs** *
*Diabetic Nephropathy Market Dynamics*
The diabetic nephropathy market dynamics are anticipated to change in the coming years. The continuous increase in cases of diabetic nephropathy presents an *opportunity for pharmaceutical companies* to introduce i*nnovative therapies* to the market. *Recent advancements* in our comprehension of diabetic nephropathy enable the d*evelopment of new drugs* targeting different aspects of the condition, ultimately aiming to halt its progression.
Several international organizations have established *clinical guidelines* with widespread consensus on recommended treatment targets, offering a unified approach to managing diabetic nephropathy. Identifying *early-stage biomarkers* in high-risk diabetic nephropathy patients enhances our ability to effectively manage the condition and mitigate its advancement. Implementing *personalized medicine* that factors in genetic and mechanistic diversity can significantly enhance renal and cardiovascular protection in diabetic individuals afflicted with diabetic nephropathy. Engaging in *strategic research endeavors* can lead to substantial progress in our understanding and clinical management of diabetes.
Furthermore, many potential therapies are being investigated for the treatment of diabetic nephropathy, and it is safe to predict that the treatment space will significantly impact the diabetic nephropathy market during the forecast period. Moreover, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the diabetic nephropathy market in the 7MM.
However, several factors may impede the growth of the diabetic nephropathy market. The diabetic nephropathy market faces hindrances due to the *absence of innovative treatment strategies* for preventing, managing, and reversing the disease. The unique *clinical variations and progression rates *in individuals with diabetic nephropathy pose substantial challenges to its effective management. Furthermore, the *lack of routine screening* and the absence of early, precise risk stratification for DKD patients contribute to the problem.
Treatment failure often results from *poor medication adherence*, exacerbating disease-related complications. Over the past two decades, the standard of care for diabetic nephropathy management has primarily relied on *risk-factor control and renin-angiotensin system (RAS) inhibition*. Additionally, inadequate *patient and primary care physician awareness* and knowledge about diabetic nephropathy remain notable issues that require attention.
*Diabetic Nephropathy Report Metrics* *Details*
Study Period 2019–2032
Diabetic Nephropathy Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Diabetic Nephropathy Market Size in 2021 USD 9.2 Billion
Key Diabetic Nephropathy Companies Prokidney, Inversago Pharma Inc., Palatin Technologies, Inc, Lexicon Pharmaceuticals, Daiichi Sankyo, CSL Behring, and others
Key Diabetic Nephropathy Therapies Renal Autologous Cell Therapy (REACT), INV-202, Bremelanotide, Ambrisentan and Sotagliflozin, Esaxerenone, CSL346, and others
*Scope of the **Diabetic Nephropathy** Market Report*
· *Therapeutic Assessment: *Diabetic Nephropathy current marketed and emerging therapies
· *Diabetic Nephropathy* *Market Dynamics:* Attribute Analysis of Emerging Diabetic Nephropathy Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Diabetic Nephropathy Market Access and Reimbursement*
Discover more about diabetic nephropathy drugs in development @ *Diabetic Nephropathy Clinical Trials*
*Table of Contents*
1. Diabetic Nephropathy Market Key Insights
2. Diabetic Nephropathy Market Report Introduction
3. Diabetic Nephropathy Market Overview at a Glance
4. Diabetic Nephropathy Market Executive Summary
5. Disease Background and Overview
6. Diabetic Nephropathy Treatment and Management
7. Diabetic Nephropathy Epidemiology and Patient Population
8. Patient Journey
9. Diabetic Nephropathy Marketed Drugs
10. Diabetic Nephropathy Emerging Drugs
11. Seven Major Diabetic Nephropathy Market Analysis
12. Diabetic Nephropathy Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Related Reports*
*Diabetic Nephropathy Epidemiology Forecast*
*Diabetic Nephropathy Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted diabetic nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
*Diabetic Nephropathy Pipeline*
*Diabetic Nephropathy Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic nephropathy companies, including *Prokidney, Inversago Pharma Inc., Palatin Technologies, Inc, Lexicon Pharmaceuticals, Daiichi Sankyo, CSL Behring**, *among others.
*Diabetic Peripheral Neuropathy Pipeline*
*Diabetic Peripheral Neuropathy Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic peripheral neuropathy companies, including *CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Helixmith, Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., Eli Lilly and Company, Daiichi Sankyo, Inc., Avazzia, Inc., *among others.
*Diabetic Neuropathy Market*
*Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast-2032 *report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including *Novo Nordisk, Ionis Pharmaceuticals, Pfizer, Regeneron, NeuroMetrix,* among others.
*Diabetic Neuropathy Pipeline*
*Diabetic Neuropathy Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including *Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, NeuroBo Pharmaceuticals, Dong-A Pharmaceutical**, *among others.
*About DelveInsight*
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*
*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*
CONTACT: Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com